Kazia Therapeutics said paxalisib reduced tumor burden by 52% in a preclinical model of microsatellite stable, proficient mismatch repair colorectal cancer, with statistical significance of p=0.035. Adding paxalisib to pembrolizumab reduced tumor volume by a further 50% versus pembrolizumab alone in a separate study, with p=0.022. Treatments were well tolerated without evidence of treatment-related toxicity. Kazia is developing biomarker analyses and plans to begin a five-arm Phase 2 trial in pre-treated MSS/pMMR metastatic colorectal cancer during the first quarter of 2027, comparing two paxalisib doses, combinations with pembrolizumab with or without biologic, and standard of care.